【摘要】 胰岛移植是治疗1型糖尿病最有希望的方法,但由于供体不足而受到限制。间充质干细胞(mesenchymal stem cells,MSC)具有自我更新和分化为3个胚层细胞的能力,是糖尿病β细胞替代治疗的另一可供选择的细胞来源。MSC能分化为β细胞替代受损的β细胞;同时MSC能迁移到受损的胰腺,通过分泌多种生物活性物质和调节性的增长因子,促进血管生成,改善β细胞生存微环境,修复受损胰腺。此外,MSC还具有调节免疫作用,通过减少自体免疫介导的对胰岛的攻击,从而阻止胰岛β细胞的进一步受损。更多还原

【Abstract】 Replacement of pancreatic cells by pancreas or islet allotransplantation represent the most promising approach for treatment of Type 1 diabetes,but it is severely limited by a shortage of donors.Mesenchymal stem cells(MSC)have the capability of self-renewal and differentiation into cells of 3 germ layers,and can offer an alternative source for β cell replacement therapy;MSC can migrate to the injured pancreas,differentiate into β cells or repair the damaged β cells by secreting various bioactive and regulatory growth factors,and promote angiogenesis which will improve the microenvironment of islet β cell activation/survive.In addition,MSC can inhibit the autoimmune-mediated attack on the new formed β-cells and in turn prevent the further damage of the islet.更多还原